Herein we report the anaerobic cleavage of alkenes into carbonyl compounds using nitroarenes as oxygen transfer reagents under visible light. This approach serves as a safe and practical alternative to mainstream oxidative cleavage protocols, such as ozonolysis and the Lemieux−Johnson reaction. A wide range of alkenes possessing oxidatively sensitive functionalities underwent anaerobic cleavage to generate carbonyl derivatives with high efficiency and regioselectivity. Mechanistic studies support that the transformation occurs via direct photoexcitation of the nitroarene followed by a nonstereospecific radical cycloaddition event with alkenes. This leads to 1,3,2-and 1,4,2-dioxazolidine intermediates that fragment to give the carbonyl products. A combination of radical clock experiments and in situ photoNMR spectroscopy revealed the identities of the key radical species and the putative aryl dioxazolidine intermediates, respectively.
A photoexcited-nitroarene-mediated anaerobic C−H hydroxylation of aliphatic systems is reported. The success of this reaction is due to the bifunctional nature of the photoexcited nitroarene, which serves as the C−H bond activator and the oxygen atom source. Compared to previous methods, this approach is cost-and atom-economical due to the commercial availability of the nitroarene, the sole mediator of the reaction. Because of the anaerobic conditions of the transformation, a noteworthy expansion in substrate scope can be obtained compared to prior reports. Mechanistic studies support that the photoexcited nitroarenes engage in successive hydrogen atom transfer and radical recombination events with hydrocarbons, leading to Narylhydroxylamine ether intermediates. Spontaneous fragmentation of these intermediates leads to the key oxygen atom transfer products.
The non-medical use of opioids has become a national crisis in the USA. Developing non-opioid pharmacotherapies for controlling this opioid epidemic is urgent. Dopamine D 3 receptor (D 3 R) antagonists and low efficacy partial agonists have shown promising profiles in animal models of opioid use disorders (OUD). However, to date, advancement to human studies has been limited. Here we report the effects of ( S )- and ( R )-enantiomers of (±)-ABS01-113, structural analogs of the D 3 R partial agonist, (±)-VK4-40, in which the 3-OH in the linking chain is replaced by 3-F group. ( S )- and ( R )-ABS01-113 are identical in chemical structure but with opposite chirality. In vitro receptor binding and functional assays indicate that ( S )-ABS01-113 is an efficacious (55%) and potent (EC 50 = 7.6 ± 3.9 nM) D 3 R partial agonist, while the ( R )-enantiomer is a potent D 3 R antagonist (IC 50 = 11.4 nM). Both ( S )- and ( R )-ABS01-113 bind with high affinity to D 3 R ( K i = 0.84 ± 0.16 and 0.37 ± 0.06 nM, respectively); however, the ( S )-enantiomer is more D 3 /D 2 -selective (>1000-fold). Pharmacokinetic analyses indicate that both enantiomers display excellent oral bioavailability and high brain penetration. Systemic administration of ( S )- or ( R )-ABS01-113 alone failed to alter open-field locomotion in male rats and mice. Interestingly, pretreatment with ( S )- or ( R )-ABS01-113 attenuated heroin-enhanced hyperactivity, heroin self-administration, and (heroin + cue)-induced reinstatement of drug-seeking behavior. Together, these findings reveal that both enantiomers, particularly the highly selective and efficacious D 3 R partial agonist ( S )-ABS01-113, demonstrate promising translational potential for the treatment of OUD.
Herein we report a visible light promoted method for the anaerobic cleavage of alkenes into carbonyl compounds using nitroarenes as oxygen transfer reagents. This approach serves as a safe and practical alternative to mainstream oxidative cleavage protocols, such as ozonolysis and the Lemieux–Johnson reaction. A wide range of alkenes possessing oxidatively sensitive functionalities underwent anaerobic cleavage to generate carbonyl derivatives with high efficiency and regioselectivity. Mechanistic studies support that the transformation occurs via a solvent-separated ion-pair complex and the nitroarene is the sole photoabsorbing species. Direct photoexcitation of the nitroarenes empowers a radical cycloaddition event with alkenes leading to a 1,3,2-dioxazolidine intermediate, which fragments to give the carbonyl products. A combination of radical clock experiments and in situ PhotoNMR spectroscopy revealed the identities of the key radical species and the putative aryl 1,3,2-dioxazolidine intermediate, respectively.
Highly selective dopamine D3 receptor (D3R) partial agonists/antagonists have been developed for the treatment of psychostimulant use disorders (PSUD). However, none have reached the clinic due to insufficient potency/efficacy or potential cardiotoxicity. Cariprazine, an FDA-approved drug for the treatment of schizophrenia and bipolar disorder, is a high-affinity D3R partial agonist (K i = 0.22 nM) with 3.6-fold selectivity over the homologous dopamine D2 receptor (D2R). We hypothesized that compounds that are moderately D3R/D2R-selective partial agonists/antagonists may be effective for the treatment of PSUD. By systematically modifying the parent molecule, we discovered partial agonists/antagonists, as measured in bioluminescence resonance energy transfer (BRET)-based assays, with high D3R affinities (K i = 0.14–50 nM) and moderate selectivity (<100-fold) over D2R. Cariprazine and two lead analogues, 13a and 13e, decreased cocaine self-administration (FR2; 1–10 mg/kg, i.p.) in rats, suggesting that partial agonists/antagonists with modest D3R/D2R selectivity may be effective in treating PSUD and potentially comorbidities with other affective disorders.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.